17-AAG: Mechanisms of antitumour activity

Expert Opinion on Investigational Drugs

Volumn 14, Issue 12, 2005, Pages 1471-1474

  Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a,c  

^a UNIVERSITY OF PATRAS   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

17 AAG; Apoptosis; Cell cycle; Chaperones; Hsp90; Hsp90 inhibitor

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; CHAPERONE; FR 901228; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; PROTEIN INHIBITOR;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CLINICAL TRIAL; CYTOSTASIS; DRUG MECHANISM; EDITORIAL; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; RIFABUTIN;

EID: 28644432986     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.12.1471     Document Type: Editorial

References (30)

1. MIYATA Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr. Pharm. Des. (2005) 11(9):1131-1138.
2. SUPKO JG, HICKMAN RL, GREVER MR, MALSPEIS L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. (1995) 36(4):305-315.
3. KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (1999) 91(22):1940-1949.
4. WHITESELL L, MIMNAUGH EG, DE COSTA B, MYERS CE, NECKERS LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA (1994) 91(18):8324-8328.
5. YOUNG JC, MOAREFI I, HARTL FU: Hsp90: a specialized but essential protein-folding tool. J. Cell Biol. (2001) 154(2):267-273.
6. BAGATELL R, WHITESELL L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. (2004) 3(8):1021-1030.
7. PRODROMOU C, ROE SM, O'BRIEN R, LADBURY JE, PIPER PW, PEARL LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 90(1):65-75.
8. SEPP-LORENZINO L, MA Z, LEBWOHL DE, VINITSKY A, ROSEN N: Herbimycin A induces the 20S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. (1995) 270(28):16580-16587.
9. HOSTEIN I, ROBERTSON D, DISTEFANO F, WORKMAN P, CLARKE PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. (2001) 61(10):4003-4009.
10. SRETHAPAKDI M, LIU F, TAVORATH R, ROSEN N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. (2000) 60(14):3940-3946.
11. BASSO AD, SOLIT DB, MUNSTER PN, ROSEN N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene (2002) 21(8):1159-1166.
12. STAHL JM, CHEUNG M, SHARMA A, TRIVEDI NR, SHANMUGAM S, ROBERTSON GP: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. (2003) 63(11):2881-2890.
13. BURGER AM, SAUSVILLE RF, CAMALIER RF et al.: Response of human melanomas to 17-AAG is associated with modulation of the molecular chaperone function of HSP90. Proceediongs of the 91st Annual Meeting of the American Association of Cancer Research, San Francisco, USA (2000) 41:447
14. JIANG J, SHAPIRO GI: 17-AAG induces Rb-dependent G1 arrest in lung cancer cell lines. Proceedings of the 93rd Annual Meeting of the American Association of Cancer Research, San Francisco, USA (2002)
15. BLAGOSKLONNY MV: p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J. (2000) 14(13):1901-1907.
16. BLAGOSKLONNY MV, TORETSKY J, BOHEN S, NECKERS L: Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA (1996) 93(16):8379-8383.
17. NIMMANAPALLI R, O'BRYAN E, KUHN D, YAMAGUCHI H, WANG HG, BHALLA KN: Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood (2003) 102(1):269-275.
18. NGUYEN DM, DESAI S, CHEN A, WEISER TS, SCHRUMP DS: Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann. Thorac. Surg. (2000) 70(6):1853-1860.
19. ISAACS JS, JUNG YJ, MIMNAUGH EG, MARTINEZ A, CUTTITTA F, NECKERS LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. (2002) 277(33):29936-29944.
20. VILLA R, FOLINI M, PORTA CD et al.: Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis (2003) 24(5):851-859.
21. NIMMANAPALLI R, O'BRYAN E, BHALLA K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. (2001) 61(5):1799-1804.
22. ZAMOYSKA R, BASSON A, FILBY A, LEGNAME G, LOVATT M, SEDDON B: The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. (2003) 191:107-118.
23. NECKERS L: Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res. (2002) 8(5):962-966.
24. BELIAKOFF J, WHITESELL L: Hsp90: an emerging target for breast cancer therapy. Anti-Cancer Drugs (2004) 15(7):651-662.
25. BANERJI U, O'DONNELL A, SCURR M et al.: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. (2005) 23(18):4152-4161.
26. SOLIT DB, ANANA M, VALENTIN G et al.: Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (pts) with advanced cancer. Am. Soc. Clin. Oncol. (2003)
27. ENMON R, YANG WH, BALLANGRUD AM et al.: Combination treatment with 17-N-allylamino- 17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. (2003) 63(23):8393-8399.
28. MUNSTER PN, BASSO A, SOLIT D, NORTON L, ROSEN N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res. (2001) 8:2228-2236. [See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res. (2001) 7:2155-2158].
29. YU X, GUO ZS, MARCU MG et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. (2002) 94(7):504-513.
30. RAHMANI M, YU C, DAI Y et al.: Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. (2003) 63(23):8420-8427.